

HEP DARTTM 2009

frontiers in drug development for viral hepatitis

DECEMBER 6-10, 2009
THE FAIRMONT ORCHID
KOHALA COAST, BIG ISLAND, HAWAII, USA



This program is sponsored by Emory University School of Medicine



EMORY
UNIVERSITY

www.HEPDART.com

CELEBRATING 20 YEARS OF HCV RESEARCH

Since 1995, the biannual HEP DART Conference has provided a unique, intimate setting that assembles clinicians, researchers and basic scientists together to advance our knowledge of the ongoing drug development processes in the treatment of hepatitis B and hepatitis C and other viruses affecting the liver, including co-infections with HIV. The 2009 DART CME-accredited Conference will uniquely blend the areas of virology, biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for hepatitis infection.



HEP DARTTM 2009

frontiers in drug development for viral hepatitis

DECEMBER 6-10, 2009

THE FAIRMONT ORCHID
KOHALA COAST, BIG ISLAND, HAWAII, USA

HEP DART 2009 is supported by independent educational grants from the following:

PREMIER SUPPORT



GOLD SUPPORT



SILVER SUPPORT



BRONZE SUPPORT



ADDITIONAL SUPPORT

Alios BioPharma, Inc. • Apath, LLC • Department of Veterans Affairs
Raymond F. Schinazi & Family Foundation • Samchully Pharm. Co., Ltd

IMPORTANT DATES

HEP DART 2009 Dates

December 6-10, 2009

Late Breaker Abstract

Submission Deadline

November 16, 2009

Late Breaker Abstract

Acceptance Notification

November 23, 2009

Final Date for Online Registration

December 2, 2009

Satellite Mini-Symposium


09:00 - December 6, 2009

Opening session of HEP DART 2009

15:00 - December 6, 2009

Closing session of HEP DART 2009

December 10, 2009



TOWARD CURATIVE THERAPIES FOR HEPATITIS C: A SATELLITE MINI-SYMPOSIUM

HEP DART attendees have a chance to hear about new developments in HCV therapeutics including combined modalities from industry leaders as well as their future plans. The mini-symposium is being held at 09:00 on December 6, 2009 prior to the official start of HEP DART 2009.

Program Information

WILLIAM H. PRUSOFF HEP DART LIFETIME ACHIEVEMENT AWARD AND LECTURE

The Long and Winding Road Leading to the Discovery of HCV

Michael Houghton, *Epiphany Biosciences, USA*

STATE OF THE ART PRESENTATIONS

The Future Burden of Chronic Liver Disease and Global Opportunities for Therapeutic Interventions

Brian McMahon, *Alaska Native Medical Center and Alaska Native Tribal Health Consortium, USA*

HCV-host Interactions - Entry and New Tools

Charles Rice, *The Rockefeller University, USA*

Understanding Stat-C by Using Cell Culture Models

Ralf Bartenschlager, *University of Heidelberg, Germany*

HBV Antiviral Drug Resistance: Prevention and Monitoring

Anna Lok, *University of Michigan Medical Center, USA*

Optimization of Anti-HCV Regimens

Michael Fried, *University of North Carolina at Chapel Hill, USA*

Pharmacology of Anti-HBV and Anti-HCV Drugs

Adrian Ray, *Gilead Sciences, Inc., USA*

Prevention of HCC in Hepatitis B Patients Using Antiviral Agents

Yun-Fan Liaw, *Chang Gung Memorial Hospital, Taiwan*

PANEL PRESENTATIONS

- HCV Education Roundtable: Anticipating a New Clinical Paradigm for Hepatitis C Virus Treatment Overcoming Resistance [*Sponsored by the Forum for Collaborative HIV Research - HCV Drug Resistance Advisory Group (DRAG)*]
- The Business of Antiviral Agents: 2010 and Beyond

GLOBAL BURDEN OF HEPATITIS VIRUSES, NATURAL HISTORY & MANAGEMENT

Brian McMahon, *Alaska Native Medical Center, USA*

Mostafa Mohamed, *Ain Shams University, Egypt*

Hashem el-Serag, *Houston Veterans Affairs Medical Center, USA*

Kenneth Sherman, *University of Cincinnati College of Medicine, USA*

DISCOVERIES & ADVANCES IN HCV BASIC RESEARCH

Harvey Alter, *National Institutes of Health, USA*

Michael Houghton, *Epiphany Biosciences, USA*

Alan Perelson, *Los Alamos National Laboratory, USA*

Timothy Tellinghuisen, *The Scripps Research Institute, USA*

Charles Rice, *The Rockefeller University, USA*

NEW TARGETS I: CELLULAR SYSTEMS AND INFECTIOUS MODELS

Ralf Bartenschlager, *University of Heidelberg, Germany*

Alexander Ploss, *The Rockefeller University, USA*

Peter Sarnow, *Stanford University, USA*

HCV MANAGEMENT: LOOKING INTO THE CRYSTAL BALL

Jean-Michel Pawlotsky, *Henri Mondor University Hospital, France*

David Nelson, *University of Florida, USA*

Adrian Di Bisceglie, *Saint Louis University School of Medicine, USA*

THE BUSINESS OF ANTIVIRAL AGENTS: 2010 AND BEYOND

Abel De La Rosa, *Pharmasset, USA*

Geoffrey Meacham, *JP Morgan Securities, Inc., USA*

Adam Cutler, *Canaccord Adams, USA*

Vivek Ramaswamy, *QVT Financial LP, USA*

David Witzke, *PioneerPath Capital, USA*

Frank Zavrl, *Adage Capital, USA*

EMERGENCE AND PREVENTION OF VIRAL RESISTANCE

Anna Lok, *University of Michigan Medical Center, USA*

Stephen Locarnini, *VIDRL, Australia*

Philippe Halfon, *Hôpital Ambroise Paré, France*

Isabel Najera, *Roche Palo Alto, USA*

Robert Gish, *CPMC, USA*

CLINICAL TRIAL DESIGN

Paul Pockros, *The Scripps Clinic, USA*

Douglas Dieterich, *Mount Sinai School of Medicine, USA*

REVIEW OF POSTER PRESENTATIONS

Adrian Di Bisceglie, *Saint Louis University School of Medicine, USA*

Adrian Ray, *Gilead Sciences, Inc., USA*

NEW TARGETS II: INSIGHTS INTO DRUG MECHANISMS

Jordan Feld, *University of Toronto, Canada*

Philippe Gallay, *The Scripps Research Institute, USA*

Thomas Pietschmann, *Center for Experimental and Clinical Infection Research, Germany*

Adam Zlotnick, *Indiana University, USA*

OPTIMIZING OUTCOME OF THERAPEUTICS FOR HEPATITIS INFECTIONS

Michael Fried, *University of North Carolina at Chapel Hill, USA*

Yves Benhamou, *Hôpital Pitié-Salpêtrière, France*

Patrick Marcellin, *Hôpital Beaujon, France*

Jules Dienstag, *Massachusetts General Hospital, USA*

PHARMACOLOGY AND NEW THERAPIES FOR HEPATITIS INFECTIONS

Adrian Ray, *Gilead Sciences, Inc., USA*

Robert Schooley, *University of California San Diego, USA*

David Strandring, *Idenix Pharmaceuticals, Inc., USA*

CO-INFECTIONS, THERAPEUTIC MODALITIES, AND REGULATORY ISSUES

Gregory Dore, *University of New South Wales, Australia*

Mark Sulkowski, *Johns Hopkins University, USA*

Richard Robson, *Christchurch Clinical Studies Trust, New Zealand*

IMMUNOLOGICAL APPROACHES & VACCINES FOR HEPATITIS INFECTIONS

Luke O'Neill, *Trinity College Dublin, Ireland*

T. Jake Liang, *NIDDK National Institutes of Health, USA*

Christoph Seeger, *Fox Chase Cancer Center, USA*

Frank Chisari, *The Scripps Research Institute, USA*

LIVER DAMAGE, DECOMPENSATION FIBROSIS & HEPATOCELLULAR CARCINOMA

(Sponsored by Hepatitis B Foundation)

Timothy Block, *Hepatitis B Foundation and Drexel Institute, USA*

Yun-Fan Liaw, *Chang Gung Memorial Hospital, Taiwan*

William Mason, *Fox Chase Cancer Center, USA*

Masao Omata, *University of Tokyo, Japan*

Nezam Afdhal, *Beth Israel Deaconess Medical Center, USA*

Thierry Poynard, *Hôpital Pitié-Salpêtrière, France*

FRAMING THE VISION

Eugene Schiff, *University of Miami, USA*

Please visit the conference website at:

www.HEPDART.com

